Introduction
Blast crisis is the terminal phase of chronic myeloid leukemia (CML), a hematopoietic malignancy characterized by the presence of the constitutively activated tyrosine kinase BCR-ABL. 1, 2 Blast crisis CML (BC-CML) is of myeloid phenotype (MBC) in approximately two-thirds of cases, and lymphoid phenotype (LBC) in the majority of remaining cases, with occasional patients having an undifferentiated or mixedlineage phenotype. 3 The prognosis for patients with all forms of BC-CML remains poor: overall survival from onset of BC is approximately 3-6 months. 4 Allogeneic stem cell transplantation (SCT) induces durable remission in <10% of patients with CML in BC, 5 and imatinib (Gleevec  ; Novartis, East Hanover, NJ) yields sustained complete hematologic responses (CHR) in <15% 5, 6 . Cytogenetic response is even rarer. 5, 6 Failure to respond to imatinib (primary resistance) is particularly common in BC compared with earlier stages of the disease. is a novel, oral, multi-targeted kinase inhibitor of BCR-ABL and SRC family kinases (SFKs), which has been rationally designed to overcome mechanisms of resistance associated with imatinib therapy. In vitro studies have shown that dasatinib has a 325-fold greater potency compared with imatinib in cells transduced with unmutated BCR-ABL, 8 and is active against all BCR-ABL mutations tested conferring imatinib resistance except one (T315I). 8, 9 This is due, at least in part, to the ability of dasatinib to bind to both the active and inactive conformations of BCR-ABL. 8 Dasatinib also inhibits the SFKs implicated in resistance to imatinib. 8, 10 In a Phase-I dasatinib doseescalation study, hematologic and cytogenetic responses were observed in all phases of imatinib-resistant and -intolerant CML as well as Philadelphia-chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), and dasatinib was very well tolerated.
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Patients and methods

Patients
Patients, aged ≥ 18 years were eligible for inclusion if they had CML in MBC or LBC and were resistant or intolerant to imatinib therapy. Blast crisis CML was defined as ≥ 30% blasts (myeloid or lymphoid) in peripheral blood or bone marrow and/or extramedullary leukemic infiltrates (other than in spleen or liver) with peripheral blood blast (myeloid or lymphoid) cell morphology.
Imatinib resistance was defined as progression from chronic phase to blast crisis while receiving imatinib ≥ 400 mg/day or from accelerated phase to blast crisis while receiving imatinib ≥ 600 mg/day (or 400-<600 mg/day if the patient was intolerant of ≥ 600 mg/day). Patients initially diagnosed in blast crisis were classified as having imatinib-resistant CML if they met the criteria for blast crisis after ≥ 4 weeks (2 weeks for patients who progressed rapidly) on imatinib ≥ 600 mg/day (or 400-<600 mg/day if the patient was intolerant of ≥ 600 mg/day). Imatinib intolerance was defined as discontinuation of therapy due to toxicity considered at least possibly related to an imatinib dose ≤ 400 mg/day or an inability to tolerate imatinib doses >400 mg/day. 
Study design and treatment
START-B and START-L were Phase-II, open-label, single-arm, multinational studies, with identical designs. These studies were conducted in accordance with the Declaration of Helsinki, and were consistent with International Conference on Harmonization Good Clinical Practice (ICH GCP) and applicable regulatory requirements. The study protocol, amendments, and patient informed consent received appropriate approval by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) prior to study initiation at each site. Written informed consent was obtained from every patient prior to clinical trial participation. START-L also included adults with Ph-positive ALL; results for these patients will be reported separately.
The primary objective of both trials was to determine the rates of major hematologic response (MaHR, which includes both complete hematologic response [CHR] and no evidence of leukemia [NEL] , as defined below) and of overall hematologic response (OHR, which includes CHR, NEL, and minor hematologic response [MiHR] ) in patients with imatinib-resistant CML in MBC or LBC following treatment with dasatinib, and to assess its safety and tolerability. Secondary objectives included the evaluation of rates of cytogenetic response (CyR), the duration of hematologic response, frequency and type of BCR-ABL mutation(s), and safety. No treatment for CML other than dasatinib was permitted during the study, except anagrelide and hydroxyurea for treatment of elevated platelet counts (>700,000/mm 3 ) and WBC count (>50,000/mm 3 ), respectively. Use of hydroxyurea was limited to a period of 2 weeks. Administration of colony-stimulating factors and recombinant erythropoietin were permitted at the discretion of the investigator.
Patient evaluation for efficacy
Patients were monitored with once-weekly complete blood counts (CBC). Confirmed hematologic responses were required to be maintained for a minimum of 4 weeks with no concomitant anagrelide or hydroxyurea used during this interval. The duration of a confirmed hematologic response was measured from the first day the criteria were met, until progression or death. Duration of response was censored at the last hematologic assessment for patients who discontinued for reasons other than progression or death. Progression in responding patients was defined as patients who achieved a MaHR or MiHR, but subsequently no longer met the criteria for MaHR or MiHR, respectively, on all assessments over a consecutive 2-week period after starting their maximum dasatinib dose. Progression was also defined as patients with no decrease from baseline levels in percentage blasts in peripheral blood or bone marrow on all assessments over a 4-week period after starting their maximum dasatinib dose.
Cytogenetic responses were evaluated by once-monthly bone marrow aspirates/biopsies for the first 3 months and every 3 months thereafter. Patients were also assessed for molecular response with real-time polymerase chain reaction (PCR) for BCR-ABL transcript levels monthly and results were expressed as a BCRFor personal use only. on November 12, 2017. by guest www.bloodjournal.org From ABL/ABL ratio. Each patient also had a pre-dose baseline blood sample collected for BCR-ABL mutation analysis. The complete ABL kinase domain of the BCR-ABL allele was analyzed using reverse transcriptase PCR (RT-PCR), followed by direct sequencing.
Patient evaluation for safety
Study drug toxicities were assessed continuously. In particular, a targeted physical examination for assessment of adverse events (AEs), including assessment of skin and mucosa, was conducted weekly for the first 2 months and every other week thereafter. Adverse events were evaluated according to the NCI CTC Version 3.0.
Statistical analysis
Efficacy analyses were performed for the treated population, which included all patients who received at least one dose of dasatinib. Two-sided 95% exact confidence intervals (CI) were calculated for the primary endpoints, CHR and OHR, using the Clopper-Pearson method. received at least one dose of study drug and were included in this analysis. In the MBC-CML cohort, 68 patients had imatinib-resistant disease and six patients were intolerant to imatinib. Reasons for imatinib intolerance were hematologic toxicity (two patients), hepatic toxicity (two patients), and rash and gastrointestinal symptoms (one patient each). In the LBC-CML cohort, 37 patients had imatinib-resistant CML and 11 five patients were imatinib-intolerant. Reasons for imatinib intolerance were hematologic toxicity (four patients) and gastrointestinal symptoms (one patient).
Patient demographics and baseline disease characteristics were representative of patients with CML in BC (Table 1) , and were generally comparable between the imatinib-resistant and -intolerant subgroups. Nearly half of all patients had received an imatinib dose of >600 mg/day and a similar proportion of the MBC-CML cohort had received imatinib for >3 years. Response to prior imatinib therapy included CHR in 84% and 67% of patients in the MBC-and LBC-CML cohorts, respectively, and a CCyR in 32% and 33% of patients prior to progression. In the MBC-CML cohort, chemotherapy had been received by 66% of patients, interferon (IFN)-α by 55%, and 12% had undergone SCT. In the LBC-CML cohort, 79% of patients had received chemotherapy, 48% IFN-α, and 33% had undergone SCT. Approximately half of all patients in both cohorts had BCR-ABL kinase mutations at baseline (MBC-CML 43%; LBC-CML 56%) ( Table 1) .
At 6 months' follow-up, 32 patients (43%) in the MBC-CML cohort remained on study, and the median duration of therapy for the total cohort was 3.5 months (<0.1-9.2 months); by 8 months' follow-up, 23 patients (31%) remained on study, and the median duration of therapy was 3.5 months (range 0.1-12.0 months) for the total MBC-CML cohort. In the LBC-CML cohort, 7 (17%) and 5 patients (12%) remained on study at 6 and 8 months' follow-up, respectively. The median duration of therapy for the total LBC-CML cohort was 2.8 months (range 0.1-6.4 months at 6 months' follow-up and 0.1-9.2 months at 8 months' follow-up). A summary of patient on-study disposition for both cohorts at 8 months' follow-up is provided in Table 2, outlining reasons for treatment discontinuation, median duration of study therapy, and median dasatinib dosage (Table 2 ).
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Efficacy
Dasatinib induced MaHR and MCyR in a significant number of patients in both MBCand LBC-CML cohorts (Tables 3 and 4) .
MBC-CML cohort. At 6 months, 32% of patients had achieved a MaHR: 34% in the imatinib-resistant subgroup and 17% in the imatinib-intolerant subgroup. These response rates increased somewhat at 8 months to 34% overall: 35% in the imatinibresistant subgroup and 17% in the imatinib-intolerant subgroup. The OHR rate was 53% (53% in the imatinib-resistant subgroup and 50% in the imatinib-intolerant subgroup) at both 6 and 8 months' follow-up.
Major hematologic responses to dasatinib occurred rapidly and were durable: median time to MaHR was 57 days (range 27-171 days) and the median duration of MaHR had not been reached at 8 months' follow-up ( Figure 1A ).
Major cytogenetic responses were observed in 23 patients (31%). Of these, 20 (87%; or 27% of the total) were complete cytogenetic responses.
Three patients (all in the imatinib-resistant subgroup) progressed. The median duration of progression-free survival in imatinib-resistant MBC-CML patients was 5.0 months ( Figure 1B ).
LBC-CML cohort.
In the LBC-CML cohort, 31% of patients achieved a MaHR (32% in the imatinib-resistant subgroup and 20% in the imatinib-intolerant subgroup) after 6 months of therapy; these response rates were maintained at 8 months' follow-up.
The OHR rate was 36% at both 6 and 8 months' follow-up (38% in the imatinibresistant subgroup and 20% in the imatinib-intolerant subgroup).
For
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Responses to dasatinib treatment were rapid and durable: median time to MaHR was 34.5 days for patients with imatinib-resistant LBC-CML, and 29 days for the patients with imatinib-intolerant LBC-CML. Response duration for the total LBC-CML cohort ranged from 1.6-8.4 months. Six of the 13 patients who achieved MaHR maintained that response at 8 months' follow-up (Figure 2A) .
A MCyR was achieved in 21 patients (50%) with LBC-CML. These included 18 patients (43%) with a CCyR.
The median duration of progression-free survival was 2.8 months ( Figure 2B ) and no imatinib-intolerant LBC-CML patient progressed (Figure 2A and 2B) .
Correlation of response with BCR-ABL genotype
Data from baseline mutational analyses of the ABL kinase domain were available for 70 of the 74 patients in the MBC-CML cohort and 40 of the 42 patients in the LBC-CML cohort (Tables 5A and 5B ).
In the MBC-CML cohort, 23 different imatinib-resistant mutations were observed in 30 patients (28 imatinib-resistant, 2 imatinib-intolerant); mutants G250E and Y253H (6 patients each) were the most common. Despite the poor prognosis for these patients, dasatinib elicited MaHRs and MCyRs in 33% and 27% of patients with any BCR-ABL mutation, respectively. Rates of MaHR and MCyR were 33% and 28% for patients with mutations in the P-loop region of the kinase. Eight of the observed mutations were associated with very high resistance to imatinib (more than a 5-fold increase in IC 50 compared with unmutated BCR-ABL in vitro: M244V, G250E, Y253H, E255K, E255V, T315I, F359V, H396R); among MBC-CML patients with these mutations, rates of MaHR and MCyR were 30% and 22%, respectively.
In the LBC-CML cohort, 16 different imatinib-resistant mutations were detected among 24 patients (23 with imatinib-resistant CML and 1 with imatinib-intolerant CML). Rates of MaHR and MCyR, respectively, were 25% and 42% in patients with any BCR-ABL mutation, 30% and 40% with P-loop mutations, and 13% and 25% with a high-resistance mutation (Table 5A and 5B).
Safety and tolerability
Dasatinib was generally well-tolerated in both cohorts, with similar tolerability reported for both imatinib-resistant and -intolerant subgroups. At 8 months' follow-up, only 11% of MBC-CML patients (all imatinib-resistant CML) had discontinued therapy due to study drug toxicity. Dose interruptions were required by 64% of patients (23% for cytopenias, 38% for non-hematologic toxicity, and 3% for other reasons), and dose escalations were introduced for 54% of patients. Among LBC-CML patients, only 1 patient (2%; imatinib-intolerant) discontinued therapy due to study drug toxicity. Dose interruptions were required for 33% of patients (19% for cytopenias, 10% for non-hematologic toxicity, and 5% for other reasons), and dose escalations were introduced for 26% of patients.
Adverse events. Non-hematologic events were generally mild-to-moderate in intensity (grade 1 or 2). The most frequent AEs of any grade related to study drug are shown in Table 6 . Gastrointestinal disorders (including diarrhea, nausea, vomiting)
were the most frequent events of any severity in both MBC-and LBC-CML cohorts.
Fluid retention events in the MBC-CML cohort included peripheral edema (19%) and pleural effusion (28%). In general, pleural effusions were reversible with temporary dose interruption, diuretics, and in some cases pulse steroids. Grade 3-4 abnormalities in albumin were reported for 2 patients (3%), in alanine aminotransferase (ALT) for 6 patients (8%), in aspartate aminotransferase (AST) for Fluid retention events of any grade appeared to occur somewhat less often in the LBC-CML cohort than in patients with MBC-CML, although rates of fatigue (29%) were higher (Table 6 ). Grade 3-4 abnormalities in albumin were reported for 2 patients (5%), in ALT for 3 patients (7%), in AST for 2 patients (5%) and in bilirubin for 3 patients (7%) ( Table 6 ).
Cytopenias. Cytopenias were common (Table 7 ) but were generally reversible in both MBC-and LBC-CML cohorts and could be managed effectively by dose interruptions or reductions. However, as might have been expected in a population of heavily pre-treated patients with CML in BC, a considerable proportion of patients had severe cytopenias prior to initiation of dasatinib therapy making assessment of the relative contribution of therapy to myelosuppression difficult in many instances. In the MBC-CML cohort at baseline, 22% of patients had severe (grade 3 or 4) neutropenia, 46% had severe thrombocytopenia, and 14% had severe anemia while in the LBC-CML cohort, 46% of patients presented with severe neutropenia, 64% had severe thrombocytopenia, and 5% had severe anemia. Febrile neutropenia (12%) was the most commonly reported grade 3-4 AE in the LBC-CML cohort, but did not result in any discontinuations from study (Table 7) .
Discussion
CML in blast crisis remains a challenging clinical entity. In this context, the results from this report (both efficacy and safety) can be considered to be of significant clinical relevance. Patients had an extensive history of CML and were heavily pretreated; 90% of patients had imatinib-resistant disease while 10% had imatinibintolerant disease. and 26% of patients with MBC-CML achieved MaHR and CHR, respectively; 31% achieved a MCyR, of which the majority (87%) were complete. Similarly, among patients with LBC-CML, 31% and 26% had achieved MaHR and CHR, and 50% achieved MCyR, 86% of which were CCyR.
Responses were usually observed rapidly. Median time for imatinib-resistant patients to achieve MaHR was approximately 1 month for the LBC-CML cohort and around 2 months for the MBC-CML group. Importantly, responses were also durable, with 74% of BC-CML patients achieving MaHR remaining progression-free with a minimum of 8 months' of follow-up.
The percentage of LBC-CML cases with major cytogenetic remission exceeded the percentage of cases with MaHR. This was due to instances in which a cytogenetic response was achieved but residual cytopenias were present, thus precluding classifying these patients as achieving a MaHR response. In these instances, we believe the cytogenetic response might be a more valuable endpoint.
The responses observed with dasatinib treatment may, at least in part, be attributable to the increased potency of dasatinib against unmutated BCR-ABL relative to imatinib, and the ability of dasatinib to inhibit a spectrum of imatinib-resistant BCR-ABL mutants. 8, 9 Mechanisms of resistance, other than mutations, have also been described, many of them BCR-ABL independent. In our study population, 36 of the 64 imatinib-resistant these patients probably contributed to the incidence and duration of apparent myelosuppression in both of these cohorts. Despite the occurrence of neutropenia with or without fever on study, no patients had discontinued therapy due to cytopenia-related infection as a result of dasatinib therapy at the time of this analysis.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Nevertheless, careful monitoring of blood counts in blast crisis patients receiving dasatinib after failure of imatinib is clearly warranted. 5, 22 Toxicity observed in these studies was reversible and can be considered acceptable in light of the available alternative therapeutic choices, including conventional cytotoxic chemotherapy, highlighting the potential benefit of this targeted molecular therapy. Importantly, patients with imatinib-intolerant CML were not disproportionately affected by cytopenia or non-hematologic AEs, suggesting that cross-intolerance between imatinib and dasatinib is minimal. Although the number of imatinib-intolerant CML patients treated was low, only 1 LBC-CML patient and no MBC-CML patients had withdrawn from study due to study drug toxicity after 8 months' follow-up.
Pleural effusions seen were reversible with dose interruption, and diuretic or steroid administration. Severe congestive heart failure/cardiac dysfunction was seen in two patients -both with myeloid blast phase disease; all patients receiving dasatinib had been heavily pre-treated with extensive prior therapies that included imatinib.
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